Treatment of Brain Metastases

Initial Medical Management

The American College of Chest Physicians recommends dexamethasone at 16 mg/day for symptomatic brain metastases to reduce cerebral edema, with a rapid taper as allowed by neurologic symptoms 2, 4
Higher doses approaching 100 mg/day may be considered for patients with more acute neurologic issues, according to the National Comprehensive Cancer Network 5
Steroid dose should be tapered as quickly as clinically possible to avoid long-term toxicity, as suggested by the National Comprehensive Cancer Network and other guidelines 5, 4
For incidentally discovered brain metastases without significant mass effect or edema, withholding steroids may be appropriate, as recommended by the National Comprehensive Cancer Network 5

MRI is the gold standard for brain metastasis diagnosis due to its higher resolution and sensitivity compared to CT, according to the National Comprehensive Cancer Network 5
Determining the number of lesions is a key first step in treatment planning, as emphasized by the National Comprehensive Cancer Network 5
Single brain metastases occur in approximately one-fourth to one-third of patients, as reported by the National Comprehensive Cancer Network 5

For 1-3 brain metastases, SRS alone is the recommended initial therapy, as suggested by the American College of Chest Physicians 1, 2, 3
For 5 or more brain metastases, WBRT is the recommended therapy, according to the American College of Chest Physicians 1, 2

Surgical resection should be considered if significant brain edema, neurologic symptoms unresponsive to steroids, or large space-occupying brain metastasis are present, as recommended by the American College of Chest Physicians and the National Comprehensive Cancer Network 1, 3, 5

The natural history of untreated cerebral metastases is poor, with median survival reported as less than 2 months, as noted by the National Comprehensive Cancer Network 5
Recursive Partitioning Analysis (RPA) classification helps determine prognosis, with Class I having the best prognosis (median survival 7.1 months) and Class III having the poorest prognosis (median survival 2.3 months), according to the National Comprehensive Cancer Network 5

Regular MRI surveillance is essential, especially for patients treated with SRS alone, as recommended by the American College of Chest Physicians 1
Patients should be monitored for steroid-related side effects and tapered as quickly as possible, as suggested by the National Comprehensive Cancer Network and other guidelines 5, 4